17例RhD血型不相合血小板输注的回顾性分析与策略  

Retrospective analysis and strategy of platelet transfusion for 17 patients with RhD incompatible platelet transfusion

作　　者：陈伟[1] 王珊[2] 李慧君 邱进 王儒彬 李强[1] 李菲[1] CHEN Wei;WANG Shan;LI Huijun;QIU Jin;WANG Rubin;LI Qiang;LI Fei(Department of Blood Transfusion,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi,830001,China;Department of Laboratory Medicine,Blood Center of Urumqi)

机构地区：[1]新疆维吾尔自治区人民医院输血科,乌鲁木齐830001 [2]乌鲁木齐市血液中心检验科

出　　处：《临床血液学杂志》2023年第2期125-127,132,共4页Journal of Clinical Hematology

基　　金：新疆维吾尔自治区人民医院院内项目(No:20190409)。

摘　　要：目的:通过回顾性分析RhD血型不相合血小板输注的患者,总结RhD不相合血小板输注的经验和应对策略。方法:利用医院六级电子病历和临床输血管理系统,获取2014至2021年血型为RhD阴性且符合研究纳入标准的17例患者,收集其基本信息、检验结果、血液输注的情况并进行统计分析。结果:17例患者ABO血型A型、B型、O型、AB型占比分别为2例(11.76%)、5例(29.41%)、9例(52.94%)、1例(5.88%);输注血小板总计51个治疗量,其中2个治疗量为RhD阴性,49个治疗量为RhD阳性;输注血小板后随访时间为28~167 d;均未见输血不良反应;不规则抗体筛查结果阴性,未见RhD及其他同种免疫反应。结论:RhD血型不相合血小板输注可有效改善患者出血及凝血相关指标,且不会引起严重的输血不良反应及免疫反应,为血小板减少症和出血患者带来益处,保障临床血小板治疗的及时性和有效性。Objective: To summarize the experience and coping strategies of RhD incompatible platelet transfusion by retrospectively analyzing the cases of RhD incompatible platelet transfusion. Methods: A total of 17 cases with RhD negative blood type from 2014 to 2021 and meeting the inclusion criteria of the study were obtained by using the level 6 electronic medical record and clinical blood transfusion management system of our hospital, and the basic information, test results and blood transfusion of patients were collected and statistically analyzed. Results: Seventeen cases of platelet transfusion with incompatible RhD blood group were obtained, and the proportion of ABO type A, B, O and AB was 2(11.76%), 5(29.41%), 9(52.94%) and 1(5.88%), respectively. A total of 51 treatment volumes were transfused, of which 2 were RhD negative and 49 were RhD positive. The follow-up time after platelet transfusion was 28-167 days. No adverse reaction of blood transfusion was observed. Irregular antibody screening results were negative, and no RhD or other alloimmune responses were observed. Conclusion: Platelet transfusion with incompatible RhD blood group could effectively improve the bleeding and coagulation related indicators of patients, and would not cause serious adverse blood transfusion reactions and immune reactions, bring benefits to patients with thrombocytopenia and bleeding, and ensure the timeliness and effectiveness of clinical platelet treatment.

关 键 词：血小板 RHD血型 不相合输注 

分 类 号：R457.1[医药卫生—治疗学]